Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor, and has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic

Rat aortic vascular smooth muscle cells (RASMCs) were treated with 1-100 μM of alagebrium added 24 hours before the addition of AGEs.?This in vivo study was done using 8-week-old male rats that were injected intraperitoneally with 80 mg/kg STZ.?Sixteen weeks later, the diabetic rats were treated with 10 mg/kg alagebrium for 4 weeks, after which carotid artery balloon injury was induced.?After 4 weeks, the animals were sacrificed for histological analysis[1].